Search details
1.
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.
Blood
; 119(15): e131-8, 2012 Apr 12.
Article
in English
| MEDLINE | ID: mdl-22289890
2.
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies.
Blood
; 116(4): 593-602, 2010 Jul 29.
Article
in English
| MEDLINE | ID: mdl-20382846
3.
Inhibition of tumor cells interacting with stromal cells by xanthones isolated from a Costa Rican Penicillium sp.
J Nat Prod
; 75(4): 793-7, 2012 Apr 27.
Article
in English
| MEDLINE | ID: mdl-22458669
4.
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
Br J Haematol
; 152(4): 420-32, 2011 Feb.
Article
in English
| MEDLINE | ID: mdl-21223249
5.
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Haematologica
; 96(8): 1170-9, 2011 Aug.
Article
in English
| MEDLINE | ID: mdl-21712538
6.
Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation.
J Immunol
; 183(12): 7799-809, 2009 Dec 15.
Article
in English
| MEDLINE | ID: mdl-19933853
7.
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Semin Hematol
; 46(2): 166-75, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19389500
8.
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
Br J Haematol
; 147(5): 672-6, 2009 Dec.
Article
in English
| MEDLINE | ID: mdl-19751238
9.
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
Mol Cancer Ther
; 7(5): 1121-9, 2008 May.
Article
in English
| MEDLINE | ID: mdl-18445657
10.
Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
Nat Med
; 30(4): 1214, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38355975
11.
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mol Cancer Ther
; 6(3): 1070-8, 2007 Mar.
Article
in English
| MEDLINE | ID: mdl-17363500
12.
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
Mol Cancer Ther
; 6(7): 1951-61, 2007 Jul.
Article
in English
| MEDLINE | ID: mdl-17620426
13.
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
J Clin Endocrinol Metab
; 92(12): 4845-52, 2007 Dec.
Article
in English
| MEDLINE | ID: mdl-17848408
14.
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
Hematol Oncol Clin North Am
; 21(6): 1007-34, vii-viii, 2007 Dec.
Article
in English
| MEDLINE | ID: mdl-17996586
15.
Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy.
Hum Gene Ther
; 17(8): 798-806, 2006 Aug.
Article
in English
| MEDLINE | ID: mdl-16942440
16.
Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.
ACS Chem Biol
; 9(5): 1086-91, 2014 May 16.
Article
in English
| MEDLINE | ID: mdl-24556163
17.
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.
Nat Rev Drug Discov
; 12(3): 217-28, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23449307
18.
Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.
Clin Cancer Res
; 19(20): 5591-601, 2013 Oct 15.
Article
in English
| MEDLINE | ID: mdl-24004671
19.
High-throughput approaches to discover novel immunomodulatory agents for cancer.
Oncoimmunology
; 1(8): 1406-1408, 2012 Nov 01.
Article
in English
| MEDLINE | ID: mdl-23243609
20.
Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ.
J Breast Cancer
; 15(3): 273-82, 2012 Sep.
Article
in English
| MEDLINE | ID: mdl-23091539